{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:27:19Z","timestamp":1767652039987,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.mayocp.2022.11.004","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T12:25:50Z","timestamp":1680697550000},"page":"676-688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Baclofen and the Risk of Encephalopathy: A\u00a0Real-World, Active-Comparator Cohort Study"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0034-2292","authenticated-orcid":false,"given":"Y. Joseph","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex R.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Brotman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Im","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mayocp.2022.11.004_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7664","article-title":"Assessment of physician prescribing of muscle relaxants in the United States, 2005-2016","volume":"3","author":"Soprano","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.mayocp.2022.11.004_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00002018-200427110-00004","article-title":"A\u00a0benefit-risk assessment of baclofen in severe spinal spasticity","volume":"27","author":"Dario","year":"2004","journal-title":"Drug Saf"},{"volume":"9","year":"2021","author":"Romito","key":"10.1016\/j.mayocp.2022.11.004_bib4"},{"issue":"11","key":"10.1016\/j.mayocp.2022.11.004_bib5","first-page":"CD012557","article-title":"Baclofen for alcohol use disorder","volume":"11","author":"Minozzi","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"20","key":"10.1016\/j.mayocp.2022.11.004_bib6","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.2019.17725","article-title":"Association of baclofen with encephalopathy in patients with chronic kidney disease","volume":"322","author":"Muanda","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocp.2022.11.004_bib7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/jcph.247","article-title":"Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations","volume":"54","author":"Vlavonou","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"7-8","key":"10.1016\/j.mayocp.2022.11.004_bib8","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1345\/aph.1E642","article-title":"Risk factors for adverse drug events: a 10-year analysis","volume":"39","author":"Evans","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.mayocp.2022.11.004_bib9","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/ndt\/gfv315","article-title":"Neurological complications in chronic kidney disease patients","volume":"31","author":"Chillon","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.mayocp.2022.11.004_bib10","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2215\/CJN.13811217","article-title":"Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation","volume":"13","author":"Shin","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.mayocp.2022.11.004_bib11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.mayocp.2022.11.004_bib12","doi-asserted-by":"crossref","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The Reporting of Studies Conducted Using Observational Routinely Collected Health Data Statement for Pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.mayocp.2022.11.004_bib13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/pds.4226","article-title":"Evaluation of algorithms to identify delirium in administrative claims and drug utilization database","volume":"26","author":"Kim","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.mayocp.2022.11.004_bib14","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/00007632-200404150-00014","article-title":"Skeletal muscle relaxant use in the United States: data from the Third National Health and Nutrition Examination Survey (NHANES III)","volume":"29","author":"Dillon","year":"2004","journal-title":"Spine (Phila Pa 1976)"},{"issue":"11","key":"10.1016\/j.mayocp.2022.11.004_bib15","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"8","key":"10.1016\/j.mayocp.2022.11.004_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5909","article-title":"Association of early physical therapy with long-term opioid use among opioid-naive patients with musculoskeletal pain","volume":"1","author":"Sun","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.mayocp.2022.11.004_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"issue":"19","key":"10.1016\/j.mayocp.2022.11.004_bib18","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"Chronic Kidney Disease Epidemiology Collaboration. New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"28","key":"10.1016\/j.mayocp.2022.11.004_bib19","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.mayocp.2022.11.004_bib20","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"issue":"446","key":"10.1016\/j.mayocp.2022.11.004_bib21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"8","key":"10.1016\/j.mayocp.2022.11.004_bib22","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.mayocp.2022.11.004_bib23","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.mayocp.2022.11.004_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-Value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mayocp.2022.11.004_bib26","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/ije\/dyaa094","article-title":"Commentary: Developing best-practice guidelines for the reporting of E-values","volume":"49","author":"VanderWeele","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"3","key":"10.1016\/j.mayocp.2022.11.004_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies [published correction appears in Epidemiology. 2010;21(4):589]","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"5","key":"10.1016\/j.mayocp.2022.11.004_bib28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bcpt.12344","article-title":"A\u00a0nationwide register-based survey of baclofen toxicity","volume":"116","author":"Kiel","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.mayocp.2022.11.004_bib29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622006498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622006498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:39:29Z","timestamp":1758418769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619622006498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0025619622006498"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.11.004","relation":{},"ISSN":["0025-6196"],"issn-type":[{"type":"print","value":"0025-6196"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baclofen and the Risk of Encephalopathy: A\u00a0Real-World, Active-Comparator Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}